Building on the general discussion on neural circuit anomalies, Kitase et al. (2025) look in a preclinical model of cerebral palsy (CP) the effects of CXCR2 immunomodulating medication on white matter integrity, motor performance, and cognitive findings. This evidence concerns the gene CXCR2 and cerebral palsy.